News
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report
Xlife Sciences AG confirms sustainable value development and strategic scaling of the portfolio in the 2024 Valuation Report. Key parameters include rNPV, cost of capital, and development risks -
-
-
COMMUNIQUÉ DE PRESSE
Xlife Sciences AG publishes 2024 Annual Report: Strategic Expansion, Technological Milestones, and International Capital Market Presence
Xlife Sciences AG publishes 2024 Annual Report highlighting strategic partnerships, technological milestones, and dual listing plans on SIX and LSE to enhance international market presence -
-
-
COMMUNIQUÉ DE PRESSE
From Lab to Unicorn: Xlife Sciences AG Portfolio Company VERAXA Biotech AG to merge with Voyager Acquisition Corp. listed on NASDAQ
Xlife Sciences AG's portfolio company VERAXA Biotech AG to merge with Voyager Acquisition Corp., valuing VERAXA at USD 1.64 billion. Nasdaq listing planned for Q4 2025 -
-
